These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2498563)

  • 21. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.
    Smith JA
    J Urol; 1984 Jun; 131(6):1110-2. PubMed ID: 6427478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of metastatic prostatic cancer.
    Paulson DF
    Urology; 1985 Feb; 25(2 Suppl):49-52. PubMed ID: 3918376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists.
    Liu SV; Schally AV; Hawes D; Xiong S; Fazli L; Gleave M; Cai J; Groshen S; Brands F; Engel J; Pinski J
    Clin Cancer Res; 2010 Sep; 16(18):4675-80. PubMed ID: 20670943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LHRH ethylamide against prostatic cancer].
    Yamanaka H; Makino T; Kumasaka F; Shida K
    Hinyokika Kiyo; 1984 Apr; 30(4):545-60. PubMed ID: 6435416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A comparison of the quality of life of prostatic cancer patients under slow releasing LH-RH analogue (TAP-144SR Depot) treatment or synthetic estrogen treatment].
    Oishi K; Arai Y; Takeuchi H; Yoshida O
    Hinyokika Kiyo; 1991 Sep; 37(9):1017-22. PubMed ID: 1785408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of very high dose D-leucine6-gonadotropin-releasing hormone proethylamide on the hypothalamic-pituitary testicular axis in patients with prostatic cancer.
    Warner B; Worgul TJ; Drago J; Demers L; Dufau M; Max D; Santen RJ
    J Clin Invest; 1983 Jun; 71(6):1842-53. PubMed ID: 6408125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.
    Allen JM; Kerle DJ; Ware H; Doble A; Williams G; Bloom SR
    Br Med J (Clin Res Ed); 1983 Dec; 287(6407):1766. PubMed ID: 6315133
    [No Abstract]   [Full Text] [Related]  

  • 29. [Contribution to studies on the treatment of cancer of the prostate with D-Trp6-LH-RH].
    Marcellino LR; Campanella A; Bandini M
    Biomed Pharmacother; 1987; 41(9-10):468-72. PubMed ID: 2968123
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine and clinical effects of leuprolide in prostatic cancer.
    Vance MA; Smith JA
    Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue.
    Trachtenberg J
    J Urol; 1983 Jun; 129(6):1149-52. PubMed ID: 6406688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III studies in prostatic cancer with leuprolide acetate.
    Seely JH
    J Androl; 1987; 8(1):S23-6. PubMed ID: 3104263
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
    Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
    J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
    [No Abstract]   [Full Text] [Related]  

  • 34. [A study of thymoma associated with cancer of the other organs].
    Tanimura S; Kouno T; Matsushita H
    Kyobu Geka; 2002 Oct; 55(11):986-9. PubMed ID: 12391698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A rare case of typical carcinoid of the lung coincident with thymoma.
    Yoshida J; Nagai K; Takahashi K; Nishimura M; Tanaka K; Kakinuma R; Nishiwaki Y; Kodama T; Hasebe T
    Jpn J Clin Oncol; 1994 Oct; 24(5):289-93. PubMed ID: 7967108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA ploidy in thymoma and associated multiple primary malignancies in the same patient.
    Sitić S; Mirt-Dabić M; Brcić L; Juros Z; Hutinec Z; Kruslin B
    Acta Clin Croat; 2008 Sep; 47(3):155-9. PubMed ID: 19175064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.
    Winfield H; Trachtenberg J
    J Urol; 1984 Jun; 131(6):1107-9. PubMed ID: 6427477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of the chronic administration of LH-RH agonist on the oral glucose tolerance test in patients with prostatic carcinoma.
    González-Bárcena D; Pérez-Sánchez P; Hernández-Meza AR; Rangel-García N; Graef-Sánchez A; Comaru-Schally AM; Schally AV
    Arch Invest Med (Mex); 1987; 18(4):273-8. PubMed ID: 2969222
    [No Abstract]   [Full Text] [Related]  

  • 39. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymic carcinoid tumor combined with thymoma--neuroendocrine differentiation in thymoma?
    Cho KJ; Ha CW; Koh JS; Zo JI; Jang JJ
    J Korean Med Sci; 1993 Dec; 8(6):458-63. PubMed ID: 8179834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.